Xeris Biopharma Inc.
XERS | NASDAQ
$8.65
-$0.15 (-1.70%)
Sep 22, 2026, 12:03 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 2.24K | -9.16 | -5.22 | -1.90 | -1.89 | -2.30 |
PEG Ratio | -22.22 | 0.52 | 0.15 | 0.03 | 0.07 | 0.06 |
PS Ratio | 4.32 | 2.45 | 1.97 | 1.64 | 4.67 | 10.27 |
PB Ratio | 92 | -16.80 | -47.71 | 3.99 | 2.43 | 6.21 |
P/FCF Ratio | 45.09 | -13.15 | -6.56 | -1.74 | -2.24 | -2.17 |
P/OCF Ratio | 43.99 | -13.45 | -6.88 | -1.75 | -2.25 | -2.20 |
OCF/S Ratio | 9.81 | -18.21 | -28.69 | -93.33 | -207.48 | -467.51 |
Debt / Equity Ratio | 2.76 | -9.17 | -33.79 | 4.38 | 0.92 | 2.58 |
Quick Ratio | 1.57 | 1.19 | 1.23 | 2.20 | 1.57 | 5.10 |
Current Ratio | 2.19 | 1.67 | 1.64 | 2.54 | 1.80 | 5.40 |
Asset Turnover | 0.76 | 0.63 | 0.51 | 0.32 | 0.16 | 0.13 |
Interest Coverage | 0.86 | -1.01 | -1.65 | -5.81 | -16.04 | -11.35 |
Return on Equity | 4.05% | 185.16% | 917.94% | -209.49% | -128.87% | -269.96% |
Return on Assets | 0.14% | -16.97% | -19.30% | -27.48% | -40.32% | -57.27% |
Return on Invested Capital | 8.89% | -13.25% | -18.68% | -29.63% | -51.11% | -63.73% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 81.70% | 81.86% | 82.52% | 79.47% | 73.14% | 54.35% |
Net Profit Margin | 0.19% | -27% | -37.98% | -85.86% | -247.48% | -446% |
Pretax Profit Margin | 0.19% | -28.12% | -38.74% | -87.15% | -247.48% | -446.54% |
Operating Profit Margin | 8.53% | -16.57% | -26.85% | -74.32% | -232.22% | -408.84% |
FCF Margin | 9.57% | -18.64% | -30.07% | -93.80% | -208.54% | -472.82% |
EBITDA Margin | 4.36% | -6.89% | -14.48% | -62.87% | -229.21% | -387.19% |
Add to Watchlist
Select watchlists to add or remove XERS